Results 91 to 100 of about 4,754 (217)

The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis

International Journal for Parasitology: Drugs and Drug Resistance, 2019
Current treatment of cutaneous leishmaniasis includes pentavalent antimonials as first-line drugs, but this therapy has shown severe adverse effects. An alternative to minimize this issue is based on combination therapy scheme with other drugs.
Luiz Filipe Gonçalves-Oliveira, Ph.D., Franklin Souza-Silva, Ph.D., Luzia Monteiro de Castro Côrtes, Ph.D., Laura Barral Veloso, Ph.D., Bernardo Acácio Santini Pereira, Ph.D., Lea Cysne-Finkelstein, Ph.D., Guilherme Curty Lechuga, Ph.D., Saulo Cabral Bourguignon, Ph.D., Fernando Almeida-Souza, Ph.D., Kátia da Silva Calabrese, Ph.D., Vitor Francisco Ferreira, Ph.D., Carlos Roberto Alves, Ph.D.   +11 more
doaj   +1 more source

Antiprotozoal Activity of Highly Substituted Pyrazole and Pyrimidine Derivatives

ChemMedChem, Volume 20, Issue 16, August 16, 2025.
Based on previously identified antimalarial agents, a series of highly substituted pyrazole and pyrimidines derivatives has been synthesized and tested for antiplasmodial and antileishmanial activity. Selected derivatives show promising antiplasmodial effect with a predicted favorable pharmacokinetic profile.
Matteo Lusardi, Nicoletta Basilico, Erika Iervasi, Chiara Brullo, Silvia Parapini, Marco Ponassi, Camillo Rosano, Andrea Spallarossa   +7 more
wiley   +1 more source

Unveiling Novel Arginase Inhibitors for Cutaneous Leishmaniasis Using Drug Repurposing and Virtual Screening Approaches

Journal of Cellular Biochemistry, Volume 126, Issue 8, August 2025.
ABSTRACT Leishmaniasis is a neglected tropical disease with a significant global health burden, particularly in developing countries, where it accounts for approximately 1.6 million new infections annually. Current therapeutic options are limited by severe adverse effects, toxicity, and drug resistance, highlighting the urgent need for novel treatment ...
Eduarda Moreira Barreto, Gabriel Rodrigues Coutinho Pereira, Isadora de Salles Arêas, Júlia Mendes Fortes, Alessandra da Silva Domingos, Lucio Mendes Cabral, Carlos Rangel Rodrigues, Alessandra Mendonça Teles de Souza, Barbara de Azevedo Abrahim‐Vieira   +8 more
wiley   +1 more source

High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls

Memorias do Instituto Oswaldo Cruz, 2003
We analyzed data from historical controls treated with meglumine antimoniate to compare the frequency of adverse events observed in patients with cutaneous leishmaniasis treated with the same dose of meglumine antimoniate contaminated with heavy metals ...
Gustavo Adolfo Sierra Romero, Érico Marlon de Moraes Flores, Elza Ferreira Noronha, Vanize de Oliveira Macêdo   +3 more
doaj   +1 more source

Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate [PDF]

Background: Pentavalent antimonials are still the first choice treatment for leishmaniasis, but with low efficacy and resistance is emerging. In the present study, the effect of meglumine antimoniate (MA, Glucantime) combined with paromomycin ...
HAKIMI PARIZI, Maryam, KHAMESIPOUR, Ali, MIRAMIN MOHAMMADI, Akram, REZAEI RIABI, Tahereh, SHARIFI, Iraj   +4 more
core  

Clinical and Parasite Species Risk Factors for Pentavalent Antimonial Treatment Failure in Cutaneous Leishmaniasis in Peru [PDF]

, 2017
Background. Treatment for cutaneous leishmaniasis (CL) with standard pentavalent antimonial therapy is hampered by cumbersome administration, toxicity, and potential failure.
Araujo-Castillo, Roger, Arevalo, Jorge, Boelaert, Marleen, Chappuis, Francois, De Doncker, Simonne, Dujardin, Jean-Claude, Lazo, Marcela, Llanos-Cuentas, Alejandro, Miranda-Verastegui, Cesar, Ramirez, Luis, Robays, Jo, Santamaria-Castrellon, Giovanna, Tulliano, Gianfranco   +12 more
core  

First Report on Infant Acute Urticaria after Mother’s Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report

Iranian Journal of Public Health, 2016
Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate ...
Omid MOZAFARI, Seyed Afshin SHOROFI, Seyde Sedighe YOUSEFI   +2 more
doaj  

Custo-efetividade de estratégias de prevenção contra a leishmaniose tegumentar americana na Argentina [PDF]

, 2013
The aim of this study was to estimate the cost-effectiveness of reducing tegumentary leishmaniasis transmission using insecticide-impregnated clothing and curtains, and implementing training programs for early diagnosis.
Orellano, Pablo Wenceslao, Salomon, Oscar Daniel, Vazquez, Néstor   +2 more
core   +1 more source

LEUCOGRAMA E METABOLISMO OXIDATIVO DOS NEUTRÓFILOS DE CÃES COM LEISHMANIOSE VISCERAL ANTES E APÓS O TRATAMENTO COM ANTIMONIATO DE MEGLUMINA E ALOPURINOL

Ciência Animal Brasileira, 2010
Leukogram and neutrophil oxidative metabolism fromdogs with visceral leishmaniasis (VL) were compared before andafter treatment with meglumine antimoniate (AM) and with anassociation of meglumine antimoniate and allopurinol (AMA).The results obtained ...
Paulo César Ciarlini, Taiana Carvalho Valadares, Fabiana Augusta Ikeda-Garcia, Mary Marcondes, Valéria Marçal Félix de Lima   +4 more
doaj  

Fever of Unknown Origin: Don’t Forget Kala-Azar Even in Europe [PDF]

, 2017
We present the case of a 70-year-old male patient with fever of unknown origin after a long period of convalescence from a previous admission to a chronic care hospital. During the admission, multiple combinations of antibiotic and antifungal treatments
De las Cuevas León, David, Martinez González, Ana, Moreno Díaz, Javier, Rubio Escuin, Rebeca   +3 more
core   +2 more sources